Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 393-396

  Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CYP2C19; CYP2D6; CYP3A4; Cytochrome P4501A2; Drug drug interactions; Drug metabolizing enzymes; Psychiatry

Indexed keywords

CARBAMAZEPINE; CLOMIPRAMINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; MIDAZOLAM; PAROXETINE; PERPHENAZINE; THIORIDAZINE; TRIAZOLAM;

CONFERENCE PAPER; DRUG EXCRETION; DRUG MONITORING; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ENZYME BINDING; ENZYME SPECIFICITY; HUMAN; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RACE DIFFERENCE;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; LIVER; MIXED FUNCTION OXYGENASES; PSYCHOTROPIC DRUGS;

EID: 0029812804     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00014     Document Type: Conference Paper

References (15)

1. Nelson DR, Kamantaki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
2. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with human liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
3. Brockmöller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994; 27:216-48.
4. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with the CYP1A2 activity determined by the caffeine test. Br J Clin Pharmacol 1994;38:471-3.
5. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993;71:1002-9.
6. deMorais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
7. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmaco-genetics 1995;5:312-7.
8. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the Ndemethylation of imipramine. Clin Pharmacol Ther 1991; 49:18-23.
9. Brøsen K, Gram LF. Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.
10. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
11. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10:545-58.
12. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-7.
13. Brøsen K, Nielsen PN, Brusgaard K, Gram LF, Skjødt K. Eur J Clin Pharmacol 1994;47:221-5.
14. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg I. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci 1993;90:11825-9.
15. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharma-cogenetics 1994;4:171-84.